Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 160

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function

Open access
Buchan, Sarah L., Dou, Lang, Remer, Marcus, Booth, Steven G., Dunn, Stuart N., Lai, Chester, Semmrich, Monika, Teige, Ingrid, Mårtensson, Linda, Penfold, Christine A., Chan, H.T. Claude, Willoughby, Jane E., Mockridge, C. Ian, Dahal, Lekh N., Cleary, Kirstie L.S., James, Sonya, Rogel, Anne, Kannisto, Päivi, Jernetz, Mats, Williams, Emily L., Healy, Eugene, Verbeek, J. Sjef, Johnson, Peter W.M., Frendéus, Björn, Cragg, Mark S., Glennie, Martin J., Gray, Juliet C., Al-Shamkhani, Aymen, Beers, Stephen A. · 2018 · Immunity

Abstract

&NA; The costimulatory receptor 4‐1BB is expressed on activated immune cells, including activated T cells. Antibodies targeting 4‐1BB enhance the proliferation and survival of antigen‐stimulated T cells in vitro and promote CD8 T cell‐dependent anti‐tumor immunity in pre‐clinical cancer models. We found that T regulatory (Treg) cells infiltrating human or murine tumors expressed high amounts of 4‐1BB. Intra‐tumoral Treg cells were preferentially depleted by anti‐4‐1BB mAbs in vivo. Anti‐4‐1BB mAbs also promoted effector T cell agonism to promote tumor rejection. These distinct mechanisms were competitive and dependent on antibody isotype and Fc&ggr;R availability. Administration of anti‐4‐1BB IgG2a, which preferentially depletes Treg cells, followed by either agonistic anti‐4‐1BB IgG1 or anti‐PD‐1 mAb augmented anti‐tumor responses in multiple solid tumor models. An antibody engineered to optimize both Fc&ggr;R‐dependent Treg cell depleting capacity and Fc&ggr;R‐independent agonism delivered enhanced anti‐tumor therapy. These insights into the effector mechanisms of anti‐4‐1BB mAbs lay the groundwork for translation into the clinic. Graphical Abstract Figure. No caption available. HighlightsAnti‐4‐1BB IgG2a depletes intratumoral Treg cells; IgG1 promotes CD8 T cell functionThe efficacy of anti‐4‐1BB mIgG1 and anti‐4‐1BB mIgG2a depends on different Fc&ggr;RsOptimal tumor therapy requires sequential anti‐4‐1BB IgG2a and IgG1 or PD‐1 blockadeHinge‐engineered anti‐4‐1BB mIgG2a/h2B mAb harnesses both mechanisms of action &NA; Buchan et al. reveal dual anti‐tumor activities for antibodies to the co‐stimulatory receptor 4‐1BB, which depend on antibody isotype and Fc&ggr;R availability. Sequential scheduling of anti‐4‐1BB and checkpoint blockade mAbs, and antibodies engineered to harness both Treg cell depleting and effector cell agonism properties show potent anti‐tumor activity in preclinical models, laying the groundwork for translation into the clinic.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.immuni.2018.09.014

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 160

Metadata

Authors
Buchan, S. L., Dou, L., Remer, M., Booth, S. G., Dunn, S. N., Lai, C., Semmrich, M., Teige, I., Mårtensson, L., Penfold, C. A., Chan, H. T. C., Willoughby, J. E., Mockridge, C. I., Dahal, L. N., Cleary, K. L. S., James, S., Rogel, A., Kannisto, P., Jernetz, M., Williams, E. L., Healy, E., Verbeek, J. S., Johnson, P. W. M., Frendéus, B., Cragg, M. S., Glennie, M. J., Gray, J. C., Al-Shamkhani, A., & Beers, S. A.
Venue
Immunity
Publisher
Elsevier BV
Published
2018-11
Volume
49
Issue
5
Pages
958-970.e7
ISSN
1074-7613 (ISSN-L)
OpenAlex
W2901938738
Cited by
160
References
8
FWCI
5.48
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function. https://app.cochat.ai/papers/10.1016/j.immuni.2018.09.014
The paper
Buchan, S. L., Dou, L., Remer, M., Booth, S. G., Dunn, S. N., Lai, C., Semmrich, M., Teige, I., Mårtensson, L., Penfold, C. A., Chan, H. T. C., Willoughby, J. E., Mockridge, C. I., Dahal, L. N., Cleary, K. L. S., James, S., Rogel, A., Kannisto, P., Jernetz, M., . . . Beers, S. A. (2018). Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function. Immunity. https://doi.org/10.1016/j.immuni.2018.09.014

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.